Iambic Therapeutics vs GE HealthCare
Side-by-side comparison of AI visibility scores, market position, and capabilities
AI drug discovery biotech with $1.7B Takeda deal (Feb 2026). Lead drug IAM1363 (brain-penetrant HER2 inhibitor) in Phase 1. $100M+ raised (2025). Founded 2019, San Diego.
About
Iambic Therapeutics was founded in 2019 with the mission of applying AI-driven drug discovery to oncology — one of the most complex and high-value areas of pharmaceutical development. The company built proprietary machine learning models for structure-based drug design, training its systems on large datasets of protein-ligand interactions to accelerate hit identification, lead optimization, and candidate selection. This computational-first approach compresses timelines that traditionally require years of iterative chemistry work into months.\n\nIambic's lead asset, IAM1363, is a brain-penetrant HER2 inhibitor targeting HER2-mutated cancers including non-small cell lung cancer and breast cancer with brain metastases — a patient population with limited treatment options and high unmet need. The candidate entered Phase 1 clinical trials as a direct output of Iambic's AI design pipeline, validating the platform's ability to produce clinically viable molecules. The company's AI models are designed to simultaneously optimize for potency, selectivity, and the blood-brain barrier permeability that makes IAM1363 differentiated from approved HER2 inhibitors.\n\nIambic secured a $1.7B collaboration deal with Takeda in February 2026, one of the largest AI drug discovery partnerships in the industry's history, validating both the platform and its pipeline at the highest commercial level. The company raised over $100M in 2025 and has positioned itself alongside Recursion and Insilico Medicine as a leading AI-first biotech with clinical-stage proof points. The Takeda deal provides non-dilutive capital and development resources while preserving Iambic's pipeline optionality across multiple oncology indications.
Chicago medical imaging and AI diagnostics (NASDAQ: GEHC) ~$19.7B FY2024 revenue; GE spinoff Jan 2023, Edison AI 100+ models, 4M+ installed devices, Alzheimer's PET tracer competing with Siemens Healthineers.
About
GE HealthCare Technologies Inc. is a Chicago, Illinois-based medical technology and digital health company — publicly traded on the NASDAQ (NASDAQ: GEHC) as an S&P 500 Health Care component — designing, manufacturing, and servicing medical imaging systems, patient monitoring equipment, pharmaceutical diagnostics, and AI-powered clinical decision support software through approximately 51,000 employees in 160 countries. GE HealthCare was spun off from General Electric Company in January 2023 — one of the most significant healthcare demergers in history — and has operated as an independent public company building its own capital structure, R&D investment priorities, and operational identity separate from GE's industrial conglomerate structure. In fiscal year 2024, GE HealthCare reported revenues of approximately $19.7 billion, with its four business segments contributing: Imaging (MRI, CT, X-ray, molecular imaging — ~$9.1B), Ultrasound (~$3.0B), Patient Care Solutions (monitoring, anesthesia — ~$3.6B), and Pharmaceutical Diagnostics (PET/SPECT contrast agents — ~$2.6B). CEO Peter Arduini has prioritized accelerating GE HealthCare's AI integration across its imaging portfolio — the Edison AI platform (100+ AI models cleared or in development for radiology workflows) embeds AI-assisted detection, workflow optimization, and image quality enhancement into GE HealthCare scanners, positioning the company as a digital health platform rather than a hardware manufacturer.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.